ALGS - Aligos Therapeutics Inc Stock Price, Fair Value and News

0.75USD+0.02 (+2.74%)Delayed as of 30 Apr 2024, 01:05 pm ET

Market Summary

USD0.75+0.02

Delayedas of 30 Apr 2024, 01:05 pm

2.74%

ALGS Stock Price

View Fullscreen

ALGS RSI Chart

ALGS Valuation

Market Cap

54.8M

Price/Earnings (Trailing)

-0.63

Price/Sales (Trailing)

5.38

EV/EBITDA

0.95

Price/Free Cashflow

-0.69

ALGS Price/Sales (Trailing)

ALGS Profitability

EBT Margin

-852.72%

Return on Equity

-95.22%

Return on Assets

-57.86%

Free Cashflow Yield

-144.14%

ALGS Fundamentals

ALGS Revenue

Revenue (TTM)

10.2M

Rev. Growth (Yr)

-67.26%

Rev. Growth (Qtr)

-46.24%

ALGS Earnings

Earnings (TTM)

-87.7M

Earnings Growth (Yr)

-27.44%

Earnings Growth (Qtr)

-54.6%

Breaking Down ALGS Revenue

52 Week Range

0.701.38

(Low)(High)

Last 7 days

-7.5%

Last 30 days

-24.5%

Last 90 days

7.2%

Trailing 12 Months

-36.2%

How does ALGS drawdown profile look like?

ALGS Financial Health

Current Ratio

5.9

ALGS Investor Care

Shares Dilution (1Y)

74.96%

Diluted EPS (TTM)

-1.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	13.9M	14.5M	12.6M	10.2M
2022	6.0M	8.2M	10.7M	13.9M
2021	0	0	0	4.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aligos Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 25, 2023	nuechterlein carole	bought	6,004,150	0.7568	7,933,600	-
Oct 25, 2023	scopa james paul	acquired	138,557	0.7568	183,083	-
Oct 25, 2023	blatt lawrence	acquired	461,858	0.7568	610,277	chief executive officer
Jun 11, 2021	woiwode thomas	acquired	-	-	18,102	-
Jun 11, 2021	woiwode thomas	acquired	-	-	2,226	-
Apr 26, 2021	woiwode thomas	acquired	-	-	18,105	-
Apr 26, 2021	woiwode thomas	acquired	-	-	2,226	-
Oct 20, 2020	woiwode thomas	bought	3,000,000	15.00	200,000	-
Oct 20, 2020	symons julian a.	acquired	-	-	18,517	see remarks
Oct 20, 2020	beigelman leonid	acquired	-	-	254,702	president

Which funds bought or sold ALGS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	ZWJ INVESTMENT COUNSEL INC	new	-	14,210	14,210	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	1,000	1,000	-%
Apr 24, 2024	Zullo Investment Group, Inc.	unchanged	-	4,108	12,740	0.01%
Apr 23, 2024	Total Clarity Wealth Management, Inc.	new	-	9,800	9,800	-%
Apr 22, 2024	Vivo Capital, LLC	unchanged	-	1,120,860	3,476,090	0.27%
Apr 19, 2024	ZRC WEALTH MANAGEMENT, LLC	unchanged	-	23.00	98.00	-%
Apr 15, 2024	Procyon Advisors, LLC	new	-	19,600	19,600	-%
Apr 05, 2024	CWM, LLC	unchanged	-	6,000	17,000	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.1	-83,195	671,736	-%
Feb 14, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	sold off	-100	-913,789	-	-%

Are Funds Buying or Selling ALGS?

Are funds buying ALGS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALGS

No. of Funds

Unveiling Aligos Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	hhlr advisors, ltd.	8.2%	5,971,426	SC 13G/A
Feb 14, 2024	armistice capital, llc	9.99%	7,214,823	SC 13G
Feb 14, 2024	ecor1 capital, llc	9.99%	7,264,147	SC 13G/A
Feb 14, 2024	alyeska investment group, l.p.	9.99%	7,176,767	SC 13G
Feb 14, 2024	baker bros. advisors lp	4.99%	3,664,013	SC 13G/A
Feb 14, 2024	tang capital partners lp	3.0%	2,189,847	SC 13G/A
Feb 08, 2024	versant venture capital vi, l.p.	1.9%	1,457,937	SC 13D/A
Nov 07, 2023	roche finance ltd	15.35%	11,025,941	SC 13G/A
Nov 06, 2023	blatt lawrence	5.3%	3,888,253	SC 13D
Nov 02, 2023	deep track capital, lp	9.99%	7,295,967	SC 13G

Recent SEC filings of Aligos Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 29, 2024	ARS	ARS
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 16, 2024	PRE 14A	PRE 14A
Mar 12, 2024	10-K	Annual Report
Mar 12, 2024	8-K	Current Report
Mar 12, 2024	S-8	Employee Benefits Plan
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Aligos Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Aligos Therapeutics Inc News

Latest updates

Aligos Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-46.2%	1,158,000	2,154,000	4,294,000	2,583,000	3,537,000	4,106,000	3,693,000	2,571,000	367,000	1,537,000	1,545,000	910,000
Operating Expenses	28.5%	28,678,000	22,310,000	26,027,000	26,641,000	26,219,000	23,054,000	24,086,000	38,128,000	38,315,000	34,605,000	31,110,000	28,650,000
S&GA Expenses	-0.3%	6,421,000	6,443,000	9,246,000	8,506,000	7,119,000	5,263,000	7,576,000	6,452,000	9,717,000	6,473,000	6,556,000	5,781,000
R&D Expenses	40.3%	22,257,000	15,867,000	16,781,000	18,135,000	19,100,000	17,791,000	16,510,000	31,676,000	28,598,000	28,132,000	24,554,000	22,869,000
EBITDA Margin	-33.0%	-8.37	-6.29	-5.48	-5.84	-6.73	-10.19	-15.11	-22.11	-28.71	-	-	-
Income Taxes	-203.4%	-30,000	29,000	757,000	39,000	49,000	-43,000	47,000	53,000	-57,000	126,000	28,000	45,000
Earnings Before Taxes	-55.0%	-27,922,000	-18,012,000	-18,034,000	-22,916,000	-21,837,000	-18,664,000	-19,877,000	-35,562,000	-37,772,000	-32,998,000	-29,790,000	-27,629,000
EBT Margin	-32.6%	-8.53	-6.43	-5.61	-5.98	-6.90	-10.42	-15.45	-22.61	-29.41	-	-	-
Net Income	-54.6%	-27,892,000	-18,041,000	-18,791,000	-22,955,000	-21,886,000	-18,621,000	-19,924,000	-35,615,000	-37,715,000	-33,124,000	-29,818,000	-27,674,000
Net Income Margin	-32.4%	-8.61	-6.50	-5.66	-5.99	-6.91	-10.42	-15.47	-22.64	-29.44	-	-	-
Free Cashflow	-11.4%	-22,658,000	-20,336,000	-13,623,000	-22,394,000	-16,874,000	-17,140,000	-25,369,000	-20,949,000	-37,816,000	-25,465,000	-23,170,000	-30,103,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	76.5%	152	86.00	106	122	147	164	183	210	235	263	212	235	265	92.00	147
Current Assets	89.0%	141	75.00	94.00	109	134	150	168	195	204	249	197	220	250	74.00	120
Cash Equivalents	92.7%	136	70.00	91.00	79.00	81.00	86.00	71.00	105	187	240	188	200	221	32.00	70.00
Net PPE	-10.6%	3.00	4.00	4.00	4.00	5.00	5.00	6.00	6.00	6.00	6.00	7.00	8.00	8.00	9.00	9.00
Liabilities	91.6%	59.00	31.00	36.00	37.00	43.00	42.00	46.00	58.00	51.00	46.00	43.00	39.00	45.00	46.00	29.00
Current Liabilities	6.4%	24.00	22.00	27.00	28.00	33.00	31.00	32.00	41.00	39.00	35.00	30.00	25.00	30.00	20.00	14.00
Shareholder's Equity	68.0%	92.00	55.00	70.00	85.00	104	122	137	153	185	217	169	195	220	-	-
Retained Earnings	-6.1%	-486	-458	-440	-422	-399	-377	-358	-338	-303	-265	-232	-202	-174	-140	-66.20
Additional Paid-In Capital	12.7%	578	513	510	506	503	499	496	491	487	483	401	398	395	4.00	1.00
Shares Outstanding	72.6%	75.00	44.00	44.00	43.00	43.00	43.00	43.00	43.00	43.00	39.00	38.00	37.00	38.00	3.00	4.00
Float	-	-	-	20.00	-	-	-	35.00	-	-	-	26.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-11.4%	-22,658	-20,336	-13,616	-22,387	-16,783	-17,137	-25,035	-20,434	-37,480	-25,368	-23,018	-29,796	-19,684	-16,566	-17,694	-20,319	-	-
Share Based Compensation	-19.5%	2,583	3,209	3,196	3,664	3,416	3,491	4,000	3,786	3,651	3,601	3,449	2,756	1,301	1,016	52.00	606	-	-
Cashflow From Investing	22.2%	-7.00	-9.00	25,004	19,993	11,604	32,483	-9,976	-60,404	-16,479	-40.00	9,848	9,693	14,937	26,656	14,931	-23,769	-	-
Cashflow From Financing	418842.9%	87,936	-21.00	414	-1.00	121	-19.00	83.00	-21.00	552	77,952	95.00	78.00	193,318	-949	27.00	-48.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALGS Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue from collaborations	$ 9,338	$ 13,907
Revenue from customers	6,191
Operating expenses:
Research and development	73,040	85,077
General and administrative	30,616	26,410
Total operating expenses	103,656	111,487
Loss from operations	(88,127)	(97,580)
Interest and other income, net	1,243	1,640
Loss before income tax expense	(86,884)	(95,940)
Income tax expense	(795)	(106)
Net loss	(87,679)	(96,046)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities	96	(57)
Gains on pension plans	48	6
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total	144	(51)
Comprehensive loss	$ (87,535)	$ (96,097)
Net loss per share, basic	$ (1.36)	$ (2.25)
Net loss per share, diluted	$ (1.36)	$ (2.25)
Weighted average shares of common stock, basic	64,260,588	42,695,227
Weighted average shares of common stock, diluted	64,260,588	42,695,227

ALGS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 135,704	$ 81,347
Restricted cash	70	115
Short-term investments		44,480
Other current assets	5,310	7,603
Total current assets	141,084	133,545
Operating lease right-of-use assets	6,559	7,698
Property and equipment, net	3,259	4,816
Other assets	625	634
Total assets	151,527	146,693
Current liabilities:
Accounts payable	2,517	4,737
Accrued liabilities	16,842	16,039
Operating lease liabilities, current	3,229	3,035
Finance lease liabilities, current	10	108
Deferred revenue from customers, current	1,224	467
Deferred revenue from collaborations, current	84	8,743
Total current liabilities	23,906	33,129
Operating lease liabilities, net of current portion	7,668	9,201
Finance lease liabilities, net of current portion	231	230
Deferred revenue from customers, net of current portion		233
Warrant liability	27,596
Long term liability	46
Total liabilities	59,447	42,793
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.
Common stock, $0.0001 par value; 320,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 75,096,906 and 42,922,980 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.	7	4
Additional paid-in capital	578,325	502,613
Accumulated deficit	(486,797)	(399,118)
Accumulated other comprehensive income	545	401
Total stockholders’ equity	92,080	103,900
Total liabilities and stockholders' equity	$ 151,527	$ 146,693

About Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ÃƒÅ¸ agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

CEO	Dr. Lawrence M. Blatt MBA, Ph.D.
WEBSITE	aligos.com
INDUSTRY	Biotechnology
EMPLOYEES	68

Aligos Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aligos Therapeutics Inc? What does ALGS stand for in stocks?

ALGS is the stock ticker symbol of Aligos Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aligos Therapeutics Inc (ALGS)?

As of Mon Apr 29 2024, market cap of Aligos Therapeutics Inc is 54.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALGS stock?

You can check ALGS's fair value in chart for subscribers.

What is the fair value of ALGS stock?

You can check ALGS's fair value in chart for subscribers. The fair value of Aligos Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aligos Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALGS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aligos Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ALGS is over valued or under valued. Whether Aligos Therapeutics Inc is cheap or expensive depends on the assumptions which impact Aligos Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALGS.

What is Aligos Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, ALGS's PE ratio (Price to Earnings) is -0.63 and Price to Sales (PS) ratio is 5.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALGS PE ratio will change depending on the future growth rate expectations of investors.